An evergreen fund established by a family office in Asia is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in local-based businesses and co-invest in businesses overseas. The fund is currently focused on new opportunities in Greater China and Southeast Asia, while they are also interested in US, Canada, and EU-based companies with a China angle.

Currently, the firm is interested in cutting edge, innovative therapeutic and platform technologies in cancer, CNS, and chronic diseases. The fund considers all stages from preclinical through pre-IPO. The fund also considers a broad range of technologies including medical devices, diagnostics, healthcare services, and nutraceuticals. In medical devices, the fund is open to all indications and prefers later stage projects with proof of concept.

The firm is looking for competent, experienced, and reliable management teams when considering investment. Prior to deciding on allocations, the fund’s management team typically spends months interacting with candidate companies to determine their track record, quality of scientific research, technical expertise, and flexibility and reliability in working with investors. The fund prefers to work with Greater China-based companies or foreign businesses that are seeking to enter the Greater China market. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a corporation has $6B in AUM and provides a variety of venture financing solutions in a mix of debt and equity structures to growth-stage companies in the technology and life science space. Initial investments typically range from $5M-$20M, with additional capital reserved for follow-on investments. The firm does not make strategic investments, but rather is focused on returns and makes all investments directly from its balance sheet; therefore, there are no time constraints for returns. The firm aims to do between $150M-$200M in deals per year. Board seats are not typically required; however, board observation rights may be required depending on the deal.

In the life science space, the firm is most interested in healthcare IT and medical devices (diagnostic or therapeutic). The firm will consider earlier-stage health IT companies without any revenue, but medical device companies must have FDA approval and would be preferred if they were generating some revenue. The firm is most interested in health IT companies with a B2B aspect, whether that be clinical or business systems, and will look at consumer-facing healthcare IT technologies on a secondary basis.

For the most part, the firm invests in North American companies, but will consider Asian companies secondarily. The firm requires that management teams have a quality track record that demonstrates their ability to execute.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A California-based firm is investing from a new fund that closed in early 2016.  The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment.  The firm invests 90% of its capital in the USA, Japan and Israel, with the remaining 10% open to global opportunities.

The firm invests in advanced therapeutics, healthcare IT, novel devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field.  Technologies of interest to the firm include 3D tissue scaffolds, organs-on-a-chip, second generation diagnostics, and single cell tracking.  The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer.  The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based large pharmaceutical firm forms partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The firm looks globally for opportunities.

The firm focuses on therapeutic assets in oncology (including immuno-oncology), immunology, and neurodegenerative diseases. The firm is also interested in fibrotic diseases of the liver (such as HBV). The firm is open to biologic, small molecule and cell therapy opportunities. The firm will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A New York based venture investment firm with a single LP looks to make growth-stage investments in the form of preferred equity, ranging from $1M-$5M initially, with additional capital reserved for follow-on financings, typically up to $10M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 2-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.

The firm makes about one-half of its investments in healthcare, and is open to any healthcare companies that do not require FDA approval for their product/service. However, the firm focuses on B2B-oriented healthcare services and healthcare IT solutions.

The firm typically looks for growing companies with a run rate of $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and will work with first-time entrepreneurs. The firm looks to take a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate VC firm that invests strategically on behalf of a biopharmaceutical company invests in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is open to opportunities worldwide.

The firm invests in three indication areas: oncology, immunology, and hematology. The fund is interested in therapeutic, medical device and healthcare IT opportunities in these three areas, but does not invest in diagnostics. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).

The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based venture capital firm established in 2014 invests in a variety of sectors including healthcare services, biotech, and medical devices. The firm typically invests $50K-$500K per company and prefers to lead investments. The firm is seeking 1-2 new investments within the next year and is open to companies based in the U.S.

The firm is open to all sectors of life science technology, though has a particular interest in healthcare services and software; therapeutics and drug discovery; and diagnostics and devices. The firm typically looks at proof-of-concept technology, and is open to preclinical technology close to receiving IND and entering clinical trials. The firm is indication agnostic.

The firm typically seeks companies that have under $5M pre-money valuations, and takes a board seat after an investment.     

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com